Top

Investigational New Drugs

Published in:

01-06-1998

Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma

Authors: Jaffer A. Ajani, Richard Pazdur, Pamela Dumas, Jackie Fairweather

Published in: Investigational New Drugs | Issue 2/1998

Title: Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma
Authors: Jaffer A. Ajani
Richard Pazdur
Pamela Dumas
Jackie Fairweather
Publication date: 01-06-1998
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 2/1998
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1023/A:1006093008179

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/1998

Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

Phase I and pharmacokinetic study of intraperitoneal topotecan

Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate

Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer

Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer